THE ONYCHOMYCOSIS PROBLEM

35 million Americans suffer from onychomycosis and FDA approved products have significant drawbacks. Oral products are associated with systemic side effects and topical products have low cure rates and require a full year of daily dosing.

THE HALLUX SOLUTION

Hallux is investigating a new approach: a subungual-topical gel (HSG) that is administered direct to the nail bed site of infection by a physician in a series of quick and easy in-office treatments.

CLINICAL TRIAL INFORMATION

An open label study of HSG to evaluate efficacy, safety, tolerability, and PK in patients with distal lateral subungual onychomycosis of the great toe will soon commence.